Engineering Human T Cells for Resistance to Methotrexate and Mycophenolate Mofetil as an In Vivo Cell Selection Strategy

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Jonnalagadda, Mahesh ^a   Brown, Christine E ^a   Chang, Wen Chung ^a   Ostberg, Julie R ^a   Forman, Stephen J ^a   Jensen, Michael C ^a,b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; EPIDERMAL GROWTH FACTOR RECEPTOR; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE 2; LENTIVIRUS VECTOR; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG; CYTOKINE; INTERLEUKIN 15;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL ENGINEERING; CELL SELECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENRICHMENT CULTURE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; SYSTEMIC THERAPY; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; LENTIVIRINAE; METABOLISM; MONONUCLEAR CELL;

ANIMALS; CELLS, CULTURED; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMP DEHYDROGENASE; INTERLEUKIN-15; LENTIVIRUS; LEUKOCYTES, MONONUCLEAR; METHOTREXATE; MICE; MYCOPHENOLIC ACID; T-LYMPHOCYTES; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 84878784192     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065519     Document Type: Article

References (39)

1. Volpato JP, Mayotte N, Fossati E, Guerrero V, Sauvageau G, et al. (2011) Selectively weakened binding of methotrexate by human dihydrofolate reductase allows rapid ex vivo selection of mammalian cells. J Mol Recognit 24: 188-198.
2. Milsom MD, Fairbairn LJ, (2004) Protection and selection for gene therapy in the hematopoietic system. J Gene Med 6: 133-146.
3. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, et al. (1996) T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2: 216-223.
4. Berger C, Flowers ME, Warren EH, Riddell SR, (2006) Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107: 2294-2302.
5. Walker RE, Carter CS, Muul L, Natarajan V, Herpin BR, et al. (1998) Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nat Med 4: 852-856.
6. Muul LM, Candotti F, (2007) Immune responses to gene-modified T cells. Curr Gene Ther 7: 361-368.
7. Abonour R, Williams DA, Einhorn L, Hall KM, Chen J, et al. (2000) Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 6: 652-658.
8. Yam P, Jensen M, Akkina R, Anderson J, Villacres MC, et al. (2006) Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells. Mol Ther 14: 236-244.
9. Sorg UR, Kleff V, Fanaei S, Schumann A, Moellmann M, et al. (2007) O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues. DNA Repair (Amst) 6: 1197-1209.
10. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, et al. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
11. June CH, (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117: 1466-1476.
12. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
13. Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, et al. (2003) High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171: 3287-3295.
14. Jena B, Dotti G, Cooper LJ, (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116: 1035-1044.
15. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, et al. (2008) Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 118: 294-305.
16. Ercikan-Abali EA, Mineishi S, Tong Y, Nakahara S, Waltham MC, et al. (1996) Active site-directed double mutants of dihydrofolate reductase. Cancer Res 56: 4142-4145.
17. Shimmura H, Tanabe K, Habiro K, Abe R, Toma H, (2006) Combination effect of mycophenolate mofetil with mizoribine on cell proliferation assays and in a mouse heart transplantation model. Transplantation 82: 175-179.
18. Allison AC, Eugui EM, (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47: 85-118.
19. Sangiolo D, Lesnikova M, Nash RA, Jensen MC, Nikitine A, et al. (2007) Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection. Gene Ther 14: 1549-1554.
20. Quemeneur L, Gerland LM, Flacher M, Ffrench M, Revillard JP, et al. (2003) Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol 170: 4986-4995.
21. McIvor RS, (1996) Drug-resistant dihydrofolate reductases: generation, expression and therapeutic application. Bone Marrow Transplant 18Suppl 3: S50-54.
22. Wang X, Chang WC, Wong CW, Colcher D, Sherman M, et al. (2011) A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118: 1255-1263.
23. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594.
24. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, et al. (2011) Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 117: 1888-1898.
25. Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, et al. (2012) Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale. J Immunother 35: 689-701.
26. Pankiewicz KW, Lesiak-Watanabe K, Watanabe KA, Malinowski K, (1999) Novel mycophenolic adenine bis(phosphonate)s as potential immunosuppressants. Curr Med Chem 6: 629-634.
27. Fossati E, Volpato JP, Poulin L, Guerrero V, Dugas DA, et al. (2008) 2-tier bacterial and in vitro selection of active and methotrexate-resistant variants of human dihydrofolate reductase. J Biomol Screen 13: 504-514.
28. Lewis WS, Cody V, Galitsky N, Luft JR, Pangborn W, et al. (1995) Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22. Kinetics, crystallography, and potential as selectable markers. J Biol Chem 270: 5057-5064.
29. Flasshove M, Banerjee D, Mineishi S, Li MX, Bertino JR, et al. (1995) Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 85: 566-574.
30. Flasshove M, Banerjee D, Bertino JR, Moore MA, (1995) Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant. Leukemia 9Suppl 1: S34-37.
31. Gatlin J, Douglas J, Evans JT, Collins RH, Wendel GD, et al. (2000) In vitro selection of lentivirus vector-transduced human CD34+ cells. Hum Gene Ther 11: 1949-1957.
32. Jonnalagadda M, Brown CE, Chang WC, Ostberg JR, Forman SJ, et al. (2013) Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase. Gene Ther.
33. Treon SP, Chabner BA, (1996) Concepts in use of high-dose methotrexate therapy. Clin Chem 42: 1322-1329.
34. Mycophenolate mofetil (CellCept) package insert (2005). Roche, USA.
35. Dubus I, Vendrely B, Christophe I, Labouyrie JP, Delmas Y, et al. (2002) Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 62: 857-867.
36. Franklin TJ, Morris WP, (1994) Pharmacodynamics of the inhibition of GTP synthesis in vivo by mycophenolic acid. Adv Enzyme Regul 34: 107-117.
37. Nguyen BT, El Sayed YM, Sadee W, (1984) Interaction among the distinct effects of adenine and guanine depletion in mouse lymphoma cells. Cancer Res 44: 2272-2277.
38. Catapano CV, Dayton JS, Mitchell BS, Fernandes DJ, (1995) GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis. Mol Pharmacol 47: 948-955.
39. Lobo ED, Balthasar JP, (2003) Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice. J Pharm Sci 92: 1654-1664.